<DOC>
	<DOCNO>NCT02502019</DOCNO>
	<brief_summary>The primary objective pilot clinical investigation ass reliability Surface Bleeding Severity Scale ( SBSS ) clinical setting . Secondary objective clinical investigation collect initial data safety efficacy HEMOBLAST™ Bellows abdominal orthopedic low extremity surgery .</brief_summary>
	<brief_title>HEMOBLAST Pilot Clinical Investigation</brief_title>
	<detailed_description>HEMOBLAST™ Bellows intend use surgical procedure adjunct hemostasis control bleed conventional procedure ineffective impractical . This prospective , multicenter , single-arm pilot clinical investigation . There 36 subject enrol across 4 investigational site . The subject follow hospital charge 6 week postoperatively . The primary endpoint clinical investigation mean pair Kappa statistic assignment SBSS score 2 Investigators . Secondary endpoint clinical investigation consist : - Proportion subject achieve hemostasis within 6 minute HEMOBLAST™ Bellows application ; - Proportion subject achieve hemostasis within 10 minute HEMOBLAST™ Bellows application ; - Proportion subject achieve hemostasis within 3 minute HEMOBLAST™ Bellows application ; - Incidence adverse event final follow-up .</detailed_description>
	<criteria>• Subject undergo elective open abdominal orthopedic low extremity surgery ; Subject authorize legal representative willing able give prior write informed consent investigation participation ; Subjects antiplatelets , include aspirin , discontinue medication least 10 day prior surgery ; Subject 21 year age old . Subject active suspect infection surgical site ; Subject Investigator able identify target bleed site ( TBS ) applicable conventional mean achieve hemostasis ineffective impractical ; Subject TBS SBSS score 1 , 2 , 3 . • Subject undergoing laparoscopic , thoracoscopic , robotic surgical procedure ; Subject undergo spinal surgical procedure ; Subject undergo neurologic surgical procedure ; Subject undergo emergency surgical procedure ; Subject pregnant , plan become pregnant followup period , actively breastfeed ; Subject clinically significant coagulation disorder disease , define platelet count &lt; 100,000 per microliter and/or International Normalized Ratio &gt; 1.5 within 4 week surgery ; Subject chronic corticosteroid use within 2 week prior surgery ; Subject receive intravenous heparin oral Coumadin within 24 hour surgery ; Subject active suspect infection surgical site ; Subject plan organ transplantation ; Subject know sensitivity allergy bovine and/or porcine substance ( ) component ( ) hemostatic agent ; Subject ASA classification &gt; 4 ; Subject life expectancy le 3 month ; Subject know psychiatric disorder , opinion Principal Investigator , would preclude subject complete clinical study ; Subject document severe congenital acquire immunodeficiency ; Subject religious objection porcine bovine component ; Subject investigational device use site cement uncemented porous coat joint implant ; Subject currently participate participate another clinical trial within past 30 day receiving/has receive investigational drug , device , biologic agent ; Subject appropriate inclusion clinical trial , per medical opinion Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>